Market Overview

Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated

Related IMMU
Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan
Mid-Morning Market Update: Markets Open Higher; Media General To Acquire Meredith For $2.4B

Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.

Posted-In: News FDA


Related Articles (IMMU)

Get Benzinga's Newsletters